D-Glucosamine Adjuvant Development Service

D-Glucosamine Adjuvant Development Service at CD BioGlyco

At CD BioGlyco, our state-of-the-art marine sugar research laboratory has kept abreast of scientific and technological trends to provide our clients with a specialized Marine Biomolecule Production service. We aim to provide our clients with unparalleled support in their glycan research. Recently, our Marine Carbohydrate-based Vaccine and Adjuvant Development Services have been recognized by our clients, especially our D-glucosamine adjuvant development service.  

• D-Glucosamine-based Immunomodulatory Adjuvant Development
  D-glucosamine binds to immunomodulators and enhances their stability and bioavailability, thereby modulating the function of the immune system.
  • In the development of D-glucosamine-based immunomodulatory adjuvants, we mainly provide the tumour immunotherapy adjuvant development service. It combines with immunomodulators (e.g. interleukin-2, interferon, etc.) to enhance their stability and bioavailability, promote the proliferation and activation of immune cells, and enhance the recognition and killing ability of tumour cells.
  • In addition, we also provide D-glucosamine therapeutic adjuvant development services targeting autoimmune diseases. For example, combining it with anti-inflammatory drugs for autoimmune diseases, such as rheumatoid arthritis, reduces inflammation and disease by modulating the function of the immune system.
  • We first identify the target vaccine and prepare D-glucosamine as the drug carrier. Then, the composition and structure of the adjuvant will be adjusted to improve the immunogenicity of the vaccine and enhance the immune response. Next, we conduct the in vitro and in vivo experiments to evaluate the immune-enhancing effect, safety, stability and other properties of the adjuvant, and to determine the optimal conditions for use. Finally, a series of clinical trials are conducted to evaluate the safety, efficacy, and immune-enhancing effects of the adjuvant and to determine the optimal dosage and regimen of use.
• D-Glucosamine-based Tissue Repair Adjuvant Development
  We use D-glucosamine as an adjuvant in combination with other drugs or bioactives to promote chondrocyte proliferation and matrix production for cartilage tissue repair and regeneration. Our adjuvant development includes but is not limited to the development of cartilage repair adjuvants, fracture healing adjuvants and tissue regeneration.
• Development of D-glucosamine-based Drug-carrying Nanoparticle Adjuvants
  We use D-glucosamine to encapsulate drugs in nanoparticles as drug carriers. These nanoparticles can achieve targeted delivery to specific tissues or cells through targeted modifications (e.g., antibodies, receptor ligands on the surface, etc.), increasing the concentration of the drug in the target area and reducing adverse effects on other normal tissues.

Fig.1 Process for the development of D-glucosamine-based drug-carrying nanoparticle adjuvants. (CD BioGlyco)

Publication Data

Technology: ELISA and histological analysis

Journal: BioMed Research International

IF: 3.246

Published: 2013

Results: This article focuses on the anti-arthritic and immunomodulatory effects of a novel glucosamine analogue called N-[2,4,5-trihydroxy-6-(hydroxymethyl) tetrahydro-2Hpyran-3-yl]acrylamide (NHAG) in rheumatoid arthritis. As mentioned in the article, NHAG is a β-D-glucosamine derivative that was synthesised through the Boullanger strategy. The study was conducted using female Sprague-Dawley rats for experiments where arthritis was induced by injection of heat-killed Mycobacterium tuberculosis MT H37Ra and treated with NHAG and the reference drug indomethacin. The experimental results showed that NHAG was able to reduce the clinical signs of arthritis, including joint swelling and redness, as well as reducing body and paw inflammation. In addition, NHAG reduced arthritis-related pain by decreasing the pain response and improving gait parameters. Finally, NHAG was found to reduce arthritis-induced joint damage by histological examination. In conclusion, NHAG has anti-arthritic and immunomodulatory effects and may be a potential drug for the treatment of rheumatoid arthritis.

Fig.2 Structure of NHAG synthesized from a parent compound glucosamine. (Shah, et al., 2013)

Applications

• D-glucosamine is often used in combination with ingredients such as chondroitin sulphate in drug development to promote joint health and reduce joint pain.
• D-glucosamine is considered to exhibit moisturising, antioxidant and anti-ageing properties and is used in skincare products.
• D-glucosamine is used as part of a vaccine adjuvant to enhance the immunological effect of a vaccine.

Advantages

• D-glucosamine increases the solubility of some poorly soluble drugs and is therefore a good adjuvant in drug development.
• We adjust and optimise the properties of specific drugs or vaccines and make a rational choice of ratios and preparation methods to achieve the best possible adjuvant effect.
• D-glucosamine as an adjuvant improves the permeability of the intestinal barrier, enhances drug permeability and promotes drug absorption.

CD BioGho provides a systematic and holistic solution for the development of D-glucosamine adjuvants. Our protocols are developed by experts with many years of experience in the field. Our broad vision provides clients with professional and high-quality scientific research project assistance. For further details, please don't hesitate to contact us.